DZ3398A1 - Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases - Google Patents

Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases

Info

Publication number
DZ3398A1
DZ3398A1 DZ013398A DZ013398A DZ3398A1 DZ 3398 A1 DZ3398 A1 DZ 3398A1 DZ 013398 A DZ013398 A DZ 013398A DZ 013398 A DZ013398 A DZ 013398A DZ 3398 A1 DZ3398 A1 DZ 3398A1
Authority
DZ
Algeria
Prior art keywords
pyrazole derivatives
kinase protein
protein inhibitors
inhibitors
kinase
Prior art date
Application number
DZ013398A
Other languages
English (en)
Inventor
Travis T Wager
Mark Allen Sanner
Christopher Blair Cooper
Christopher John Helal
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ3398A1 publication Critical patent/DZ3398A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ013398A 2000-08-31 2001-08-24 Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases DZ3398A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31
PCT/IB2001/001540 WO2002018346A1 (fr) 2000-08-31 2001-08-24 Derives pyrazole et leur utilisation en tant qu'inhibiteurs des proteines kinases

Publications (1)

Publication Number Publication Date
DZ3398A1 true DZ3398A1 (fr) 2002-03-07

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013398A DZ3398A1 (fr) 2000-08-31 2001-08-24 Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases

Country Status (38)

Country Link
EP (1) EP1313710A1 (fr)
JP (1) JP2004507526A (fr)
KR (1) KR20030027093A (fr)
CN (1) CN1518543A (fr)
AP (1) AP2001002266A0 (fr)
AR (1) AR035345A1 (fr)
AU (1) AU2001280009A1 (fr)
BG (1) BG107455A (fr)
BR (1) BR0113574A (fr)
CA (1) CA2420363A1 (fr)
CR (1) CR6881A (fr)
CZ (1) CZ2003468A3 (fr)
DO (1) DOP2001000243A (fr)
DZ (1) DZ3398A1 (fr)
EA (1) EA200300205A1 (fr)
EC (1) ECSP034480A (fr)
EE (1) EE200300085A (fr)
GT (1) GT200100179A (fr)
HN (1) HN2001000192A (fr)
HR (1) HRP20030140A2 (fr)
HU (1) HUP0302669A3 (fr)
IL (1) IL154016A0 (fr)
IS (1) IS6687A (fr)
MA (1) MA26946A1 (fr)
MX (1) MXPA03001785A (fr)
NO (1) NO20030958D0 (fr)
NZ (1) NZ523656A (fr)
OA (1) OA12368A (fr)
PA (1) PA8528101A1 (fr)
PE (1) PE20020470A1 (fr)
PL (1) PL360742A1 (fr)
SK (1) SK2002003A3 (fr)
SV (1) SV2002000618A (fr)
TN (1) TNSN01132A1 (fr)
UY (1) UY26909A1 (fr)
WO (1) WO2002018346A1 (fr)
YU (1) YU14703A (fr)
ZA (1) ZA200301064B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2005504093A (ja) * 2001-09-27 2005-02-10 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 内因性テストステロンレベルの増加方法
WO2003068229A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
EP2324825A1 (fr) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylurées dotées d'une activité d'inhibition de l'angiogenèse
ATE393159T1 (de) * 2002-07-17 2008-05-15 Pfizer Italia Srl Heterobicyclische pyrazolderivate als kinaseinhibitoren
AU2003263518A1 (en) 2002-10-09 2004-05-04 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
JP2006504755A (ja) * 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
JP2006519234A (ja) * 2003-02-27 2006-08-24 スミスクライン ビーチャム コーポレーション 新規化合物
ATE384264T1 (de) 2003-05-20 2008-02-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe mit kinasehemmender wirkung
WO2005009344A2 (fr) * 2003-06-05 2005-02-03 Elan Pharmaceuticals, Inc. Amino acide amidyle pyrazoles acyles et composes relatifs
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CA2532231A1 (fr) * 2003-07-25 2005-02-03 Pfizer Inc. Composes d'aminopyrrazoles et leur utilisation comme inhibiteurs de la chk1
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US20090227648A1 (en) * 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006004865A1 (fr) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. Composés de quinoléine de substitution et leurs utilisations comme inhibiteurs de la cascade de signalement du récepteur d'immunoglobuline (ige)
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
WO2006055831A2 (fr) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Inhibiteurs de kinase
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
CN101155800B (zh) 2005-02-04 2012-05-23 阿斯利康(瑞典)有限公司 可用作激酶抑制剂的吡唑基氨基吡啶衍生物
WO2006085685A1 (fr) * 2005-02-09 2006-08-17 Takeda Pharmaceutical Company Limited Dérivé de pyrazole
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
MX2007014328A (es) 2005-05-16 2008-02-12 Astrazeneca Ab Compuestos quimicos.
EP1741708A1 (fr) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Amides heterocycliques substitués contenant un linker cyclique ou insaturé, et leur utilisation comme agent pharmaceutique
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
US7563787B2 (en) 2005-09-30 2009-07-21 Miikana Therapeutics, Inc. Substituted pyrazole compounds
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006307657B2 (en) 2005-10-28 2010-10-28 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
NZ594383A (en) 2005-11-03 2013-05-31 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
EP2416155A1 (fr) 2006-10-18 2012-02-08 Periness Ltd. Sélection de spermatozoides dans une population pour utilisation dans la reproduction assistée
JP5406030B2 (ja) * 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2117538A1 (fr) 2007-01-24 2009-11-18 Glaxo Group Limited Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2009017453A1 (fr) * 2007-07-30 2009-02-05 Astrazeneca Ab Nouvelle combinaison thérapeutique d'antipsychotique et d'inhibiteur de gsk3 958
EA019104B1 (ru) 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
HUE027598T2 (en) 2009-04-03 2016-10-28 Hoffmann La Roche Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
US20110081316A1 (en) * 2009-10-02 2011-04-07 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
CA2780190C (fr) 2009-11-06 2020-05-05 Plexxikon, Inc. Composes et methodes de modulation des kinases et leurs indications d'emploi
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
ES2671398T3 (es) * 2013-08-16 2018-06-06 Merck Patent Gmbh Derivados de ciclopentilamina 3-sustituida
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱***症的药物组合物
JP2022516057A (ja) 2018-12-31 2022-02-24 バイオメア フュージョン，エルエルシー メニン－ｍｌｌ相互作用の不可逆的阻害剤
WO2020142559A1 (fr) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibiteurs de l'interaction ménine-mll
WO2020157652A2 (fr) * 2019-01-31 2020-08-06 Pfizer Inc. Inhibiteurs de cdk2
WO2022135442A1 (fr) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Inhibiteur de cdk2 et son procédé de préparation
CN117897384A (zh) 2021-06-28 2024-04-16 缆图药品公司 Cdk2抑制剂
TW202317564A (zh) * 2021-07-01 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2抑制劑及其製備方法和用途
WO2023083201A1 (fr) * 2021-11-09 2023-05-19 上海拓界生物医药科技有限公司 Dérivé d'aminopyrazole, son procédé de préparation et son utilisation
WO2023092088A1 (fr) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Inhibiteurs de cdk2 et leurs procédés de fabrication et d'utilisation
WO2023239629A1 (fr) * 2022-06-06 2023-12-14 Plexium, Inc. Composés et compositions pharmaceutiques qui dégradent cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101704A3 (en) * 1997-12-22 2002-12-28 Bayer Corp Pittsburgh Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
AU6314900A (en) * 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EE200200275A (et) * 1999-11-30 2003-10-15 Pfizer Products Inc. Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
WO2001079198A1 (fr) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases

Also Published As

Publication number Publication date
YU14703A (sh) 2006-05-25
HRP20030140A2 (en) 2003-04-30
AP2001002266A0 (en) 2001-09-30
ECSP034480A (es) 2003-03-31
CN1518543A (zh) 2004-08-04
EE200300085A (et) 2004-12-15
ZA200301064B (en) 2004-04-19
WO2002018346A1 (fr) 2002-03-07
AU2001280009A1 (en) 2002-03-13
MXPA03001785A (es) 2003-06-04
CZ2003468A3 (cs) 2004-05-12
PE20020470A1 (es) 2002-06-18
OA12368A (en) 2004-04-13
HUP0302669A2 (hu) 2003-12-29
IL154016A0 (en) 2003-07-31
HUP0302669A3 (en) 2004-03-29
HN2001000192A (es) 2001-08-28
IS6687A (is) 2003-01-16
CA2420363A1 (fr) 2002-03-07
KR20030027093A (ko) 2003-04-03
BR0113574A (pt) 2003-07-22
AR035345A1 (es) 2004-05-12
TNSN01132A1 (fr) 2005-11-10
MA26946A1 (fr) 2004-12-20
NZ523656A (en) 2004-11-26
SK2002003A3 (en) 2004-04-06
NO20030958L (no) 2003-02-28
DOP2001000243A (es) 2002-10-15
PA8528101A1 (es) 2002-07-30
EP1313710A1 (fr) 2003-05-28
UY26909A1 (es) 2002-03-22
PL360742A1 (en) 2004-09-20
BG107455A (en) 2003-09-30
JP2004507526A (ja) 2004-03-11
EA200300205A1 (ru) 2003-06-26
CR6881A (es) 2004-03-11
SV2002000618A (es) 2002-10-24
GT200100179A (es) 2002-04-22
NO20030958D0 (no) 2003-02-28

Similar Documents

Publication Publication Date Title
DZ3398A1 (fr) Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
ATE318814T1 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
PT1317448E (pt) Compostos de pirazole uteis como inibidores de proteina-quinase
PT1345922E (pt) Compostos de pirazole uteis como inibidores de proteina-quinase
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
FR13C0003I2 (fr) Inhibiteurs cycliques de proteine tyrosine kinase
AU2728201A (en) 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
NO20023713D0 (no) 2-benzotiazolyl-urea-derivater samt anvendelse derav som proteinkinaseinhibitorer
DE122008000002I1 (de) Pyrrol substituierte indolin-2-on protein kinase inhibitoren
EE200200576A (et) Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
CY2014034I1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
NO20021820D0 (no) Tyrosinkinaseinhibitorer
HK1053832A1 (zh) 蛋白激酶抑制劑
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2002358198A1 (en) Benzimidazole derivatives and their use as kdr protein kinase inhibitors
IL172840A (en) Benzimidazole history and their use as a protein kinase inhibitor